Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh

被引:0
|
作者
Shahinul Alam [1 ]
Sheikh Mohammad Noor-E-Alam [1 ]
Ziaur Rahman Chowdhury [1 ]
Mahabubul Alam [1 ]
Jahangir Kabir [1 ]
机构
[1] Department of Hepatology,Bangabandhu Sheikh Mujib Medical University,Shahbag,Dhaka 1000,Bangladesh
关键词
Fatty liver; Gamma-glutamyl transpeptidase; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Alanine aminotransferase; Obesity; Basal metabolic index;
D O I
暂无
中图分类号
R575.1 [肝炎];
学科分类号
1002 ; 100201 ;
摘要
AIM: To explore the prevalence and risk factors for nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) patients. METHODS: We have included 493 patients with sonographic evidence of a fatty change, and 177 of these individuals were evaluated and confirmed after liver biopsy. The exclusion criteria consisted of significant alcohol abuse (< 20 g daily), evidence of hepatitis B and C, evidence of drug-induced fatty liver disease and other specific liver diseases such as hemochromatosis, Wilson’s disease or autoimmune liver disease. The patients were assessed for metabolic syndrome, and biochemical, anthropometric and histopathological evaluations were carried out. The degree of disease activity in the NAFLD patients was evaluated using the NAFLD Activity Score. The data were analyzed by SPSS, version 16.0. RESULTS: Females predominated among the study participants (250, 57.0%), and the mean age was 40.8 ± 10.2 years. The numbers of overweight, obeseⅠ and obese Ⅱ patients were 58 (13.2%), 237 (53.9%) and 93 (21.2%), respectively. However, there were 422 (96.2%) centrally obese patients. NASH was absent in 10 (5.6%) cases, borderline in 92 (52.6%) cases and present in 75 (42.4%) cases. The presence of diabetes could significantly (P = 0.001) differentiate NASH from simple steatosis. The following parameters did not influence the development of NASH: age, sex, basal metabolic index, waist circumference, serum high-density lipoprotein, triglyceride, insulin resistance index, hypertension and metabolic syndrome. The serum gammaglutamyl transpeptidase (GGT) level was significantly higher (P = 0.05, 51.7 ± 32.8 and 40.4 ± 22.6 U/L) in the NASH patients, with a sensitivity of 45% and a specificity of only 68%. The serum alanine aminotransferase and aspartate aminotransferase levels were not able to predict NASH. CONCLUSION: Females were the predominant sufferers of NAFLD in Bangladesh. The prevalence of NASH was high. Diabetes was found to be the main culprit in developing NASH. GGT was the only biochemical marker of NASH. We recommend liver biopsy in NAFLD patients who have diabetes and elevated GGT.
引用
收藏
页码:281 / 287
页数:7
相关论文
共 50 条
  • [31] Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
    Mohammadi, Zahra
    Poustchi, Hossein
    Hekmatdoost, Azita
    Etemadi, Arash
    Eghtesad, Sareh
    Sharafkhah, Maryam
    Stewart, Delisha
    Ghanbari, Reza
    Chlipala, George Edward
    Bishehsari, Faraz
    Merat, Shahin
    Malekzadeh, Reza
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2022, 27 (01):
  • [32] Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Fierbinteanu-Braticevici, Carmen
    Baicus, Cristian
    Tribus, Laura
    Papacocea, Raluca
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2011, 20 (02) : 153 - 159
  • [33] Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Patients with Morbid Obesity
    Manno, Emilio
    [J]. OBESITY SURGERY, 2010, 20 (06) : 811 - 811
  • [34] Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
    Lee, Hye Won
    Park, Soo Young
    Kim, Seung Up
    Jang, Jae Young
    Park, Hana
    Kim, Ja Kyung
    Lee, Chun Kyon
    Chon, Young Eun
    Han, Kwang-Hyub
    [J]. PLOS ONE, 2016, 11 (06):
  • [35] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [36] Can Nutritional Supplements Benefit Patients With Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease?
    Baradeiya, Ahmed M.
    Taghlabi, Khaled M.
    Saleh, Abdelhalim N.
    Manikonda, Sindhura
    Salim, Siffat S.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [37] Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
    Younossi, Zobair M.
    Marchesini, Giulio
    Pinto-Cortez, Helena
    Petta, Salvatore
    [J]. TRANSPLANTATION, 2019, 103 (01) : 22 - 27
  • [38] Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis Sarcopenia and Nonalcoholic Fatty Liver Disease
    Kawaguchi, Takumi
    Takahashi, Hirokazu
    Gerber, Lynn H.
    [J]. CLINICS IN LIVER DISEASE, 2023, 27 (02) : 275 - 286
  • [39] GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE
    Yilmaz, Y.
    Ayyildiz, T.
    Akin, H.
    Colak, Y.
    Ozturk, O.
    Senates, E.
    Tuncer, I.
    Dolar, E.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S553 - S554
  • [40] Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Yoshihisa Takahashi
    Keiichiro Sugimoto
    Hiroshi Inui
    Toshio Fukusato
    [J]. World Journal of Gastroenterology, 2015, 21 (13) : 3777 - 3785